Cargando…

Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II

Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is X-linked recessive lysosomal storage disorder resulting from the defective activity of the enzyme iduronate-2-sulfatase (IDS). Hunter disease can vary from mild to severe, depending on the level of enzyme deficiency. We report the IDS mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Chkioua, Latifa, Khedhiri, Souhir, Ferchichi, Salima, Tcheng, Rémy, Chahed, Henda, Froissart, Roseline, Vianey-Saban, Christine, Laradi, Sandrine, Miled, Abdelhedi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3115838/
https://www.ncbi.nlm.nih.gov/pubmed/21605424
http://dx.doi.org/10.1186/1746-1596-6-42
_version_ 1782206176420691968
author Chkioua, Latifa
Khedhiri, Souhir
Ferchichi, Salima
Tcheng, Rémy
Chahed, Henda
Froissart, Roseline
Vianey-Saban, Christine
Laradi, Sandrine
Miled, Abdelhedi
author_facet Chkioua, Latifa
Khedhiri, Souhir
Ferchichi, Salima
Tcheng, Rémy
Chahed, Henda
Froissart, Roseline
Vianey-Saban, Christine
Laradi, Sandrine
Miled, Abdelhedi
author_sort Chkioua, Latifa
collection PubMed
description Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is X-linked recessive lysosomal storage disorder resulting from the defective activity of the enzyme iduronate-2-sulfatase (IDS). Hunter disease can vary from mild to severe, depending on the level of enzyme deficiency. We report the IDS mutation and polymorphisms causing the Hunter syndrome in patients from one family in Tunisia PATIENTS AND METHODS: A preliminary diagnosis was made by qualitative detection of urinary glycosaminoglycans of the suspected MPS II probands. The IDS mutation and polymorphisms were determined on these probands and their family members by amplifying and sequencing each of the exons and intron-exon junctions of IDS gene. RESULTS: The studied probands were homoallelic for p.R88P mutation. In addition, three known polymorphisms/sequence variants: IVS3-16 (c.419-16 delT), T214M (c.641C > T), T146T (c.438 C > T), IVS5-87(c.709-87G > A) and one previously unknown: IVS7+38(c.1006+38T > C were identified in the MPS II patients. These are the first Tunisian MPS II patients to be genotyped. CONCLUSION: The identification of these mutation and polymorphisms and their genotype-phenotype correlation should facilitate prenatal diagnosis and counseling for MPS II in Tunisia, where a very high rate of consanguinity exists.
format Online
Article
Text
id pubmed-3115838
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31158382011-06-16 Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II Chkioua, Latifa Khedhiri, Souhir Ferchichi, Salima Tcheng, Rémy Chahed, Henda Froissart, Roseline Vianey-Saban, Christine Laradi, Sandrine Miled, Abdelhedi Diagn Pathol Case Report Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is X-linked recessive lysosomal storage disorder resulting from the defective activity of the enzyme iduronate-2-sulfatase (IDS). Hunter disease can vary from mild to severe, depending on the level of enzyme deficiency. We report the IDS mutation and polymorphisms causing the Hunter syndrome in patients from one family in Tunisia PATIENTS AND METHODS: A preliminary diagnosis was made by qualitative detection of urinary glycosaminoglycans of the suspected MPS II probands. The IDS mutation and polymorphisms were determined on these probands and their family members by amplifying and sequencing each of the exons and intron-exon junctions of IDS gene. RESULTS: The studied probands were homoallelic for p.R88P mutation. In addition, three known polymorphisms/sequence variants: IVS3-16 (c.419-16 delT), T214M (c.641C > T), T146T (c.438 C > T), IVS5-87(c.709-87G > A) and one previously unknown: IVS7+38(c.1006+38T > C were identified in the MPS II patients. These are the first Tunisian MPS II patients to be genotyped. CONCLUSION: The identification of these mutation and polymorphisms and their genotype-phenotype correlation should facilitate prenatal diagnosis and counseling for MPS II in Tunisia, where a very high rate of consanguinity exists. BioMed Central 2011-05-23 /pmc/articles/PMC3115838/ /pubmed/21605424 http://dx.doi.org/10.1186/1746-1596-6-42 Text en Copyright ©2011 Chkioua et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Chkioua, Latifa
Khedhiri, Souhir
Ferchichi, Salima
Tcheng, Rémy
Chahed, Henda
Froissart, Roseline
Vianey-Saban, Christine
Laradi, Sandrine
Miled, Abdelhedi
Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II
title Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II
title_full Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II
title_fullStr Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II
title_full_unstemmed Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II
title_short Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II
title_sort molecular analysis of iduronate -2- sulfatase gene in tunisian patients with mucopolysaccharidosis type ii
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3115838/
https://www.ncbi.nlm.nih.gov/pubmed/21605424
http://dx.doi.org/10.1186/1746-1596-6-42
work_keys_str_mv AT chkioualatifa molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii
AT khedhirisouhir molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii
AT ferchichisalima molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii
AT tchengremy molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii
AT chahedhenda molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii
AT froissartroseline molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii
AT vianeysabanchristine molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii
AT laradisandrine molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii
AT miledabdelhedi molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii